Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
Key Points
Added 458,295 shares of Cytokinetics, a $25,187,893 net position change
Transaction represents a 13.8% position relative to 13F reportable assets under management
Post-trade stake: 458,295 shares valued at $25,187,893
CYTK is now the fund’s 2nd-largest holding by reported U.S. equity positions
- These 10 stocks could mint the next wave of millionaires ›
What happened
Foresite Capital Management IV, LLC disclosed a new stake in Cytokinetics (NASDAQ:CYTK), adding 458,295 shares valued at $25.19 million as of Sept. 30, 2025. The move was detailed in a quarterly report filed with the U.S. Securities and Exchange Commission on Nov. 14, 2025 (SEC filing). The fund’s total reportable U.S. equity assets stood at $182.61 million across six holdings after the filing.
What else to know
- This is a new position for Foresite Capital Management IV, LLC, representing 13.8% of reportable assets under management as of the Sept. 30, 2025, filing.
- Top holdings after the filing:
- NASDAQ: PHVS: $119.23 million (70.3% of AUM)
- NASDAQ: CYTK: $25.19 million (14.9% of AUM)
- NASDAQ: MAZE: $13.55 million (8.0% of AUM)
- NASDAQ: LYEL: $12.99 million (7.1% of AUM)
- NASDAQ: XENE: $6.42 million (3.8% of AUM)
- As of Nov. 14, 2025, shares of Cytokinetics were priced at $66.44, up 21.5% over the past year, outperforming the S&P 500 by 6.2 percentage points.
Company overview
| Metric | Value |
|---|---|
| Market capitalization | $7.90 billion |
| Price (as of market close 2025-11-14) | $66.44 |
| Revenue (TTM) | $87.21 million |
| Net income (TTM) | ($751.94 million) |
Company snapshot
- Develops and commercializes small-molecule drug candidates targeting muscle function, including cardiac and skeletal muscle activators and inhibitors in late-stage clinical trials.
- Operates a biotechnology business model focused on R&D, clinical advancement, and strategic partnerships to generate revenue through licensing, collaborations, and eventual product sales.
- Targets healthcare providers and institutions treating patients with heart failure, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, and hypertrophic cardiomyopathy.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company specializing in muscle biology, with a pipeline of novel therapies in advanced clinical development. The company leverages proprietary expertise in muscle contractility to address unmet medical needs in serious cardiovascular and neuromuscular diseases. Strategic alliances and a focused R&D approach position Cytokinetics to compete in the biotechnology sector targeting high-impact therapeutic areas.
Foolish take
Foresite's bet on Cytokinetics in the third quarter was a relatively big one for the fund. It was the only new position added in the third quarter. Despite being a new addition, it was the fund's second-largest holding with a value of $25.2 million at the end of September.
The Foresite Capital Management IV fund added to just one other position during the third quarter. It added 368,000 shares to its Pharvaris position, which ended up worth $119 million at the end of the quarter.
Cytokinetics is awaiting an approval decision from the U.S. Food and Drug Administration (FDA) regarding its application for aficamten as a treatment for patients with obstructive hypertrophic cardiomyopathy (HCM). In September, the company met with the agency's representatives regarding a risk evaluation and mitigation strategy program.
In May, cytokinetics announced that aficamten met its primary goal in a pivotal trial. Patients with HCM who recived the treatment showed significantly improved peak oxygen uptake levels compared to folks randomized to receive standard care.
Glossary
Assets under management (AUM): The total market value of investments managed on behalf of clients by a fund or firm.
13F reportable assets: U.S. equity holdings that institutional investment managers must disclose quarterly to the SEC using Form 13F.
Position: The amount of a particular security or asset held by an investor or fund.
Net position change: The difference in the value or number of shares of a holding after a transaction.
Stake: The ownership interest or share an investor holds in a company.
Biotechnology business model: A company structure focused on research, development, and commercialization of biological products, often involving partnerships and licensing.
Late-stage clinical trials: Advanced phases of testing new drugs or treatments in humans before seeking regulatory approval.
Strategic partnerships: Formal collaborations between companies to achieve specific business objectives, such as research, development, or commercialization.
Licensing: Granting rights to use intellectual property, such as drug compounds, in exchange for payments or royalties.
Pipeline: The portfolio of drug candidates a biopharmaceutical company is developing, often at various stages.
Proprietary expertise: Specialized knowledge or technology owned and developed by a company.
TTM: The 12-month period ending with the most recent quarterly report.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 991%* — a market-crushing outperformance compared to 195% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
See the stocks »
*Stock Advisor returns as of December 8, 2025
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cytokinetics. The Motley Fool has a disclosure policy.
Recommended Articles
